Irinotecan liposomes for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with extensive-stage small cell lung cancer (cancer that has spread beyond the lung)
- Your cancer has gotten worse after at least 6 months of first-line treatment that included platinum chemotherapy (like carboplatin or cisplatin)
- You have at least one tumor that can be measured on a scan
- You are in generally good health, with a performance status score of 0-2 (meaning you are up and active most of the day)
- You have adequate kidney, liver, and blood cell counts as shown by recent lab tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs, including liposomal irinotecan, as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard options.
This study tests a new drug (cirtuvivint) combined with irinotecan, a common chemotherapy, for people whose small cell lung cancer has progressed after at least one prior treatment. The goal is to see if the combination helps control the cancer and whether it is safe.
This trial tests a new combination treatment with irinotecan liposome for advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line therapy. It aims to see if this treatment can help control the cancer and improve outcomes.
This trial tests a chemotherapy drug called irinotecan liposomes for people with high-grade neuroendocrine tumors or neuroendocrine cancers of the digestive system. The goal is to see if this treatment can help shrink or control the tumors.
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.